● Recruiting

meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis

Condition: Peritoneal Dialysis Complication · End Stage Kidney Disease · Sodium-glucose Co-transporter-2 Inhibitors · Sponsor: University Health Network, Toronto

PhasePhase 3

Planned participants20

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The primary aim of this study is to determine the safety and mechanisms of SGLT2 inhibition in individuals on peritoneal dialysis (PD) with residual kidney function (RKF).

This description comes directly from the study's public registry record.

Talk to the study team

Vesta Lai · 416-340-4800 · vesta.lai@uhn.ca

Always discuss trial participation with your own doctor first.

Locations (1)

Toronto General Hospital

Toronto, Ontario, Canada

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05715814